PETALING JAYA: Nova MSC Bhd
, via its subsidiary EyRIS Pte Ltd, has secured a contract worth RM7.13mil from JPMCnova Sdn Bhd to Roll out of the National Diabetic Retinopathy (DR) Screening Program in Brunei Darussalam.
Nova, a provider of industry-focused application software and services for the healthcare sector, said in a statement Brunei is one of the earliest countries in the world to strengthen its public health system by integrating a deep learning system into their national DR screening program. It said the five-year project is set to commence in October 2024 and will use EyRIS’ advanced artificial intelligence platforms across hospitals and healthcare centres in the country.
“This marks a significant step forward in Brunei’s healthcare strategy as the country confronts a growing diabetic population, currently estimated at 13.3%, which translates to approximately 40,000 citizens. “With DR being the number one cause of vision impairment, a systematic approach to early detection of DR is crucial to ensure early treatment and prevent vision loss.”
